Esperion Therapeutics

Yahoo Finance • 2 months ago

Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?

We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic... Full story

Yahoo Finance • 7 months ago

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 11 months ago

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet... Full story

Yahoo Finance • 11 months ago

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. – Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of... Full story

Yahoo Finance • last year

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the... Full story

Yahoo Finance • last year

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced... Full story

Yahoo Finance • last year

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Inc... Full story

Yahoo Finance • last year

Esperion Therapeutics Inc (ESPR) Reports 79% Y/Y Growth in Q3 Total Revenue

Esperion Therapeutics Inc (NASDAQ:ESPR) reports a 79% year-over-year (Y/Y) increase in Q3 total revenue, reaching $34.0 million. U.S. net product revenue grew by 45% Y/Y to $20.3 million, driven by retail prescription growth of 33% Y/Y. Re... Full story

Yahoo Finance • last year

Esperion Reports Third Quarter 2023 Financial Results

– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Ac... Full story

Yahoo Finance • last year

Esperion to Report Third Quarter 2023 Financial Results on November 7

ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023. Following the release, management wil... Full story

Yahoo Finance • last year

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will pa... Full story

Yahoo Finance • last year

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk redu... Full story

Yahoo Finance • last year

Esperion to Report Second Quarter 2023 Financial Results on August 1

ANN ARBOR, Mich., July 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. Following the release, management will... Full story

Yahoo Finance • last year

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

ANN ARBOR, Mich., July 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at the 2023 ASPC Congress on CVD Prevention taking place on July 21-23, 2023, in Arlington, TX. Session Type:... Full story

Yahoo Finance • last year

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the applica... Full story

Yahoo Finance • last year

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

– 30% risk reduction of MACE-4 composite of death from cardiovascular causes, and >25% risk reduction across four key secondary endpoints in primary prevention population, including 27% reduction in all-cause mortality – – Bempedoic acid... Full story

Yahoo Finance • last year

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment with statin therapy per unit decrease i... Full story

Yahoo Finance • last year

Not Many Are Piling Into Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Yet As It Plummets 28%

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares have had a horrible month, losing 28% after a relatively good period beforehand. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 75% loss during t... Full story

Yahoo Finance • 2 years ago

Esperion Reports First Quarter 2023 Financial Results

– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position with $56 Million in Financing – – Global... Full story

Yahoo Finance • 2 years ago

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”) and filed an amended complaint against... Full story